{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:53:53Z","timestamp":1774004033297,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-40138-w","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T07:59:55Z","timestamp":1771315195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Artificial Intelligence-based characterization of therapeutic response in fluid types and volumes influencing retinal function in neovascular age-related macular degeneration"],"prefix":"10.1038","volume":"16","author":[{"given":"Sophie","family":"Frank-Publig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf","family":"Buehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Mares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard M.","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Eidenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Scheschy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Faustmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Gumpinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emese","family":"S\u00fckei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hrvoje","family":"Bogunovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor S.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sacu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Schmidt-Erfurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"40138_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/s2214-109x(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong, W. L. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2, e106\u2013116. https:\/\/doi.org\/10.1016\/s2214-109x(13)70145-1 (2014).","journal-title":"Lancet Glob Health"},{"key":"40138_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/bjophthalmol-2017-311258","volume":"102","author":"RRA Bourne","year":"2018","unstructured":"Bourne, R. R. A. et al. Prevalence and causes of vision loss in high-income countries and in Eastern and central Europe in 2015: magnitude, Temporal trends and projections. Br. J. Ophthalmol. 102, 575\u2013585. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311258 (2018).","journal-title":"Br. J. Ophthalmol."},{"key":"40138_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/s0140-6736(22)02609-5","volume":"401","author":"RH Guymer","year":"2023","unstructured":"Guymer, R. H. & Campbell, T. G. Age-related macular degeneration. Lancet 401, 1459\u20131472. https:\/\/doi.org\/10.1016\/s0140-6736(22)02609-5 (2023).","journal-title":"Lancet"},{"key":"40138_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla, T. A., Hussain, R. M., Pollack, J. S. & Williams, D. F. Visual acuity outcomes and Anti-Vascular endothelial growth factor therapy intensity in neovascular Age-Related macular degeneration patients: A Real-World analysis of 49 485 eyes. Ophthalmol. Retina. 4, 19\u201330. https:\/\/doi.org\/10.1016\/j.oret.2019.05.017 (2020).","journal-title":"Ophthalmol. Retina"},{"key":"40138_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","volume":"4","author":"AM Khanani","year":"2020","unstructured":"Khanani, A. M. et al. SIERRA-AMD: A Retrospective, Real-World evidence study of patients with neovascular Age-Related macular degeneration in the united States. Ophthalmol. Retina. 4, 122\u2013133. https:\/\/doi.org\/10.1016\/j.oret.2019.09.009 (2020).","journal-title":"Ophthalmol. Retina"},{"key":"40138_CR6","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.2147\/opth.S49385","volume":"7","author":"JM Rakic","year":"2013","unstructured":"Rakic, J. M. et al. Real-world variability in Ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin. Ophthalmol. 7, 1849\u20131858. https:\/\/doi.org\/10.2147\/opth.S49385 (2013).","journal-title":"Clin. Ophthalmol."},{"key":"40138_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz, F. G. et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br. J. Ophthalmol. 99, 220\u2013226. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305327 (2015).","journal-title":"Br. J. Ophthalmol."},{"key":"40138_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/ceo.13949","volume":"49","author":"V Nguyen","year":"2021","unstructured":"Nguyen, V., Barthelmes, D. & Gillies, M. C. Neovascular age-related macular degeneration: A review of findings from the real-world fight retinal Blindness! Registry. Clin. Exp. Ophthalmol. 49, 652\u2013663. https:\/\/doi.org\/10.1111\/ceo.13949 (2021).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"40138_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.oret.2025.01.010","volume":"9","author":"DWT Yap","year":"2025","unstructured":"Yap, D. W. T., Tan, B. K. J., Chong, K. T. Y., Wong, T. Y. & Cheung, C. M. G. Persistence of retinal fluid after Anti-VEGF treatment for neovascular Age-Related macular degeneration: A systematic review and Meta-Analysis. Ophthalmol. Retina. 9, 603\u2013617. https:\/\/doi.org\/10.1016\/j.oret.2025.01.010 (2025).","journal-title":"Ophthalmol. Retina"},{"key":"40138_CR10","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy, U. et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye (Lond). 35, 2983\u20132990. https:\/\/doi.org\/10.1038\/s41433-020-01354-4 (2021).","journal-title":"Eye (Lond)"},{"key":"40138_CR11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","volume":"127","author":"U Schmidt-Erfurth","year":"2020","unstructured":"Schmidt-Erfurth, U., Vogl, W. D., Jampol, L. M. & Bogunovi\u0107, H. Application of automated quantification of fluid volumes to Anti-VEGF therapy of neovascular Age-Related macular degeneration. Ophthalmology 127, 1211\u20131219. https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.010 (2020).","journal-title":"Ophthalmology"},{"key":"40138_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2023.10.017","author":"GS Reiter","year":"2023","unstructured":"Reiter, G. S. et al. Long-term effect of fluid volumes during the maintenance phase in neovascular age-related macular degeneration: results from fight retinal Blindness! Can. J. Ophthalmol. https:\/\/doi.org\/10.1016\/j.jcjo.2023.10.017 (2023).","journal-title":"Can. J. Ophthalmol."},{"key":"40138_CR13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/bjo-2022-323014","volume":"108","author":"V Mares","year":"2024","unstructured":"Mares, V. et al. Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine. Br. J. Ophthalmol. 108, 971\u2013977. https:\/\/doi.org\/10.1136\/bjo-2022-323014 (2024).","journal-title":"Br. J. Ophthalmol."},{"key":"40138_CR14","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer, R. H. et al. Tolerating subretinal fluid in neovascular Age-Related macular degeneration treated with Ranibizumab using a Treat-and-Extend regimen: FLUID study 24-Month results. Ophthalmology 126, 723\u2013734. https:\/\/doi.org\/10.1016\/j.ophtha.2018.11.025 (2019).","journal-title":"Ophthalmology"},{"key":"40138_CR15","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1097\/iae.0000000000003180","volume":"41","author":"C Grechenig","year":"2021","unstructured":"Grechenig, C. et al. Retina 41, 2221\u20132228, doi:https:\/\/doi.org\/10.1097\/iae.0000000000003180 (2021).","journal-title":"Retina"},{"key":"40138_CR16","doi-asserted-by":"publisher","first-page":"100972","DOI":"10.1016\/j.preteyeres.2021.100972","volume":"86","author":"U Schmidt-Erfurth","year":"2022","unstructured":"Schmidt-Erfurth, U. et al. AI-based monitoring of retinal fluid in disease activity and under therapy. Prog Retin Eye Res. 86, 100972. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.100972 (2022).","journal-title":"Prog Retin Eye Res."},{"key":"40138_CR17","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1167\/iovs.16-21053","volume":"58","author":"H Bogunovic","year":"2017","unstructured":"Bogunovic, H. et al. Prediction of Anti-VEGF treatment requirements in neovascular AMD using a machine learning approach. Invest. Ophthalmol. Vis. Sci. 58, 3240\u20133248. https:\/\/doi.org\/10.1167\/iovs.16-21053 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"40138_CR18","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1038\/s41598-022-09642-7","volume":"12","author":"TC Yeh","year":"2022","unstructured":"Yeh, T. C. et al. Prediction of treatment outcome in neovascular age-related macular degeneration using a novel convolutional neural network. Sci. Rep. 12, 5871. https:\/\/doi.org\/10.1038\/s41598-022-09642-7 (2022).","journal-title":"Sci. Rep."},{"key":"40138_CR19","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/s41433-022-02077-4","volume":"37","author":"U Schmidt-Erfurth","year":"2023","unstructured":"Schmidt-Erfurth, U. et al. Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis. Eye (Lond). 37, 1160\u20131169. https:\/\/doi.org\/10.1038\/s41433-022-02077-4 (2023).","journal-title":"Eye (Lond)"},{"key":"40138_CR20","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/s41433-022-02154-8","volume":"37","author":"LM Coulibaly","year":"2023","unstructured":"Coulibaly, L. M. et al. Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)-a phase III, prospective, multicentre, randomized study: design and methods. Eye (Lond). 37, 1464\u20131469. https:\/\/doi.org\/10.1038\/s41433-022-02154-8 (2023).","journal-title":"Eye (Lond)"},{"key":"40138_CR21","doi-asserted-by":"publisher","first-page":"251584142210833","DOI":"10.1177\/25158414221083363","volume":"14","author":"GS Reiter","year":"2022","unstructured":"Reiter, G. S. & Schmidt-Erfurth, U. Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy. Ther. Adv. Ophthalmol. 14, 25158414221083363. https:\/\/doi.org\/10.1177\/25158414221083363 (2022).","journal-title":"Ther. Adv. Ophthalmol."},{"key":"40138_CR22","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/iae.0000000000003557","volume":"42","author":"BS Gerendas","year":"2022","unstructured":"Gerendas, B. S. et al. Retina 42, 1673\u20131682, doi:https:\/\/doi.org\/10.1097\/iae.0000000000003557 (2022).","journal-title":"Retina"},{"key":"40138_CR23","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ophtha.2017.10.031","volume":"125","author":"T Schlegl","year":"2018","unstructured":"Schlegl, T. et al. Fully automated detection and quantification of macular fluid in OCT using deep learning. Ophthalmology 125, 549\u2013558. https:\/\/doi.org\/10.1016\/j.ophtha.2017.10.031 (2018).","journal-title":"Ophthalmology"},{"key":"40138_CR24","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide, R. F. et al. Consensus nomenclature for reporting neovascular Age-Related macular degeneration data: consensus on neovascular Age-Related macular degeneration nomenclature study group. Ophthalmology 127, 616\u2013636. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004 (2020).","journal-title":"Ophthalmology"},{"key":"40138_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/aos.17458","author":"M Michl","year":"2025","unstructured":"Michl, M. et al. Comparison of AI-based retinal fluid monitoring in neovascular age-related macular degeneration with manual assessment by different eye care professionals under optimized conditions. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.17458 (2025).","journal-title":"Acta Ophthalmol."},{"key":"40138_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth, U. et al. Intravitreal Aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121, 193\u2013201. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.011 (2014).","journal-title":"Ophthalmology"},{"key":"40138_CR27","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein, S. M. et al. Morphology and visual acuity in Aflibercept and Ranibizumab therapy for neovascular Age-Related macular degeneration in the VIEW trials. Ophthalmology 123, 1521\u20131529. https:\/\/doi.org\/10.1016\/j.ophtha.2016.03.037 (2016).","journal-title":"Ophthalmology"},{"key":"40138_CR28","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1111\/aos.14905","volume":"100","author":"S Llorente-Gonz\u00e1lez","year":"2022","unstructured":"Llorente-Gonz\u00e1lez, S. et al. The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age-related macular degeneration long-term treated in real world. Acta Ophthalmol. 100, e521\u2013e531. https:\/\/doi.org\/10.1111\/aos.14905 (2022).","journal-title":"Acta Ophthalmol."},{"key":"40138_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41598-021-03716-8","volume":"12","author":"PK Roberts","year":"2022","unstructured":"Roberts, P. K. et al. Baseline predictors for subretinal fibrosis in neovascular age-related macular degeneration. Sci. Rep. 12, 88. https:\/\/doi.org\/10.1038\/s41598-021-03716-8 (2022).","journal-title":"Sci. Rep."},{"key":"40138_CR30","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/iae.0000000000003023","volume":"41","author":"GS Reiter","year":"2021","unstructured":"Reiter, G. S. et al. Retina 41, 1318\u20131328, doi:https:\/\/doi.org\/10.1097\/iae.0000000000003023 (2021).","journal-title":"Retina"},{"issue":"Suppl 1","key":"40138_CR31","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1097\/iae.0000000000001271","volume":"36","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. A prospective study. Retina 36 (Suppl 1), S50\u2013s64. https:\/\/doi.org\/10.1097\/iae.0000000000001271 (2016).","journal-title":"Retina"},{"key":"40138_CR32","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1097\/iae.0000000000002195","volume":"38","author":"AM Khanani","year":"2018","unstructured":"Khanani, A. M. et al. Retina 38, 2103\u20132117, doi:https:\/\/doi.org\/10.1097\/iae.0000000000002195 (2018).","journal-title":"Retina"},{"key":"40138_CR33","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1097\/iae.0000000000003881","volume":"43","author":"A Berlin","year":"2023","unstructured":"Berlin, A. et al. Inflammatory cell activity in treated neovascular age-related macular degeneration: A histologic case study. Retina 43, 1904\u20131913. https:\/\/doi.org\/10.1097\/iae.0000000000003881 (2023).","journal-title":"Retina"},{"key":"40138_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2011-301236","volume":"96","author":"S Binder","year":"2012","unstructured":"Binder, S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br. J. Ophthalmol. 96, 1\u20132. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-301236 (2012).","journal-title":"Br. J. Ophthalmol."},{"key":"40138_CR35","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/09273948.2024.2306129","volume":"32","author":"M Wang","year":"2024","unstructured":"Wang, M. et al. Bioinformatics and network Pharmacology explore the role of immune cells in the occurrence of Anti-Vascular endothelial growth factor (VEGF) resistance in patients with neovascular Age-Related macular Degeneration(nAMD) and the application of complementary medicine treatment. Ocul Immunol. Inflamm. 32, 1945\u20131960. https:\/\/doi.org\/10.1080\/09273948.2024.2306129 (2024).","journal-title":"Ocul Immunol. Inflamm."},{"key":"40138_CR36","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2147\/dddt.S97653","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang, S., Zhao, J. & Sun, X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des. Devel Ther. 10, 1857\u20131867. https:\/\/doi.org\/10.2147\/dddt.S97653 (2016).","journal-title":"Drug Des. Devel Ther."},{"key":"40138_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ophtha.2019.09.021","volume":"127","author":"JS Heier","year":"2020","unstructured":"Heier, J. S. et al. Intravitreal combined Aflibercept\u2009+\u2009Anti-Platelet-Derived growth factor receptor \u03b2 for neovascular Age-Related macular degeneration: results of the phase 2 CAPELLA trial. Ophthalmology 127, 211\u2013220. https:\/\/doi.org\/10.1016\/j.ophtha.2019.09.021 (2020).","journal-title":"Ophthalmology"},{"key":"40138_CR38","doi-asserted-by":"publisher","unstructured":"Kubicka-Trz\u0105ska, A. et al. Genetic variants of complement factor H Y402H (rs1061170), C2 R102G (rs2230199), and C3 E318D (rs9332739) and response to intravitreal Anti-VEGF treatment in patients with exudative Age-Related macular degeneration. Med. (Kaunas). 58. https:\/\/doi.org\/10.3390\/medicina58050658 (2022).","DOI":"10.3390\/medicina58050658"},{"key":"40138_CR39","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.ophtha.2013.01.014","volume":"120","author":"F Abedi","year":"2013","unstructured":"Abedi, F. et al. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmology 120, 1641\u20131648. https:\/\/doi.org\/10.1016\/j.ophtha.2013.01.014 (2013).","journal-title":"Ophthalmology"},{"key":"40138_CR40","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/bjophthalmol-2014-305488","volume":"99","author":"Z Hu","year":"2015","unstructured":"Hu, Z., Xie, P., Ding, Y., Yuan, D. & Liu, Q. Association between variants A69S in ARMS2 gene and response to treatment of exudative AMD: a meta-analysis. Br. J. Ophthalmol. 99, 593\u2013598. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305488 (2015).","journal-title":"Br. J. Ophthalmol."},{"key":"40138_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/bjo.2011.203893","volume":"96","author":"MS Egh\u00f8j","year":"2012","unstructured":"Egh\u00f8j, M. S. & S\u00f8rensen, T. L. Tachyphylaxis during treatment of exudative age-related macular degeneration with Ranibizumab. Br. J. Ophthalmol. 96, 21\u201323. https:\/\/doi.org\/10.1136\/bjo.2011.203893 (2012).","journal-title":"Br. J. Ophthalmol."},{"key":"40138_CR42","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3341\/kjo.2015.29.4.226","volume":"29","author":"DRC Moon","year":"2015","unstructured":"Moon, D. R. C., Lee, D. K., Kim, S. H., You, Y. S. & Kwon, O. W. Aflibercept treatment for neovascular Age-related macular degeneration and polypoidal choroidal vasculopathy refractory to Anti-vascular endothelial growth factor. Korean J. Ophthalmol. 29, 226\u2013232. https:\/\/doi.org\/10.3341\/kjo.2015.29.4.226 (2015).","journal-title":"Korean J. Ophthalmol."},{"key":"40138_CR43","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/s0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta, P. et al. Intravitreal Aflibercept 8\u00a0mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 403, 1141\u20131152. https:\/\/doi.org\/10.1016\/s0140-6736(24)00063-1 (2024).","journal-title":"Lancet"},{"key":"40138_CR44","doi-asserted-by":"publisher","unstructured":"Samac\u00e1-Samac\u00e1, D. et al. Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis. BMJ Open. Ophthalmol. 9 https:\/\/doi.org\/10.1136\/bmjophth-2024-001702 (2024).","DOI":"10.1136\/bmjophth-2024-001702"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40138-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:39:52Z","timestamp":1773995992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40138-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40138"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40138-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.S.R declares to have acted as a consultant for Apellis, Bayer, Boehringer Ingelheim, Espansione, Nordic Pharma and Roche and received research fundings paid to the institution from RetInSight. US-E is a scientific consultant for AbbVie, ADARx, Alcon, Alkeus, Allergan, Annexon, Apellis, Astellas, Aviceda, Bayer, Boehringer Ingelheim, Complement Therapeutics, EcoR1, Janssen, Kodiak, Medscape, Novartis, ONL and Roche. These activities are not related to this project. The other authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9466"}}